Clamp AR - Search Results

1

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.

Blagden SP, Cook AD, Poole C, Howells L, McNeish IA, Dean A, Kim JW, O'Donnell DM, Hook J, James EC, White IR, Perren T, Lord R, Dark G, Earl HM, Hall M, Kaplan R, Ledermann JA, Clamp AR. Blagden SP, et al. Among authors: clamp ar. Lancet Oncol. 2020 Jul;21(7):969-977. doi: 10.1016/S1470-2045(20)30218-7. Lancet Oncol. 2020. PMID: 32615110 Free PMC article. Clinical Trial.

2

Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies.

Clamp A, Danson S, Clemons M. Clamp A, et al. Lancet Oncol. 2002 Oct;3(10):611-9. doi: 10.1016/s1470-2045(02)00875-6. Lancet Oncol. 2002. PMID: 12372723 Review.

3

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

Clamp A, Adams M, Atkinson R, Boven E, Calvert AH, Cervantes A, Ganesan T, Lotz J, Vasey P, Cheverton P, Jayson GC. Clamp A, et al. Gynecol Oncol. 2004 Oct;95(1):114-9. doi: 10.1016/j.ygyno.2004.06.047. Gynecol Oncol. 2004. PMID: 15385119 Clinical Trial.

4

Assessment of therapeutic response in patients with metastatic bone disease.

Clamp A, Danson S, Nguyen H, Cole D, Clemons M. Clamp A, et al. Lancet Oncol. 2004 Oct;5(10):607-16. doi: 10.1016/S1470-2045(04)01596-7. Lancet Oncol. 2004. PMID: 15465464 Review.

5

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.

Clamp AR, Mäenpää J, Cruickshank D, Ledermann J, Wilkinson PM, Welch R, Chan S, Vasey P, Sorbe B, Hindley A, Jayson GC; Scottish Gynaecological Cancer Trials Group. Clamp AR, et al. Br J Cancer. 2006 Jan 16;94(1):55-61. doi: 10.1038/sj.bjc.6602910. Br J Cancer. 2006. PMID: 16404360 Free PMC article. Clinical Trial.

6

The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma.

Rosa DD, Clamp A, Mullamitha S, Ton NC, Lau S, Byrd L, Clayton R, Slade RJ, Kitchener HC, Shanks JH, Wilson G, McVey R, Hasan J, Swindell R, Jayson GC. Rosa DD, et al. Eur J Surg Oncol. 2006 Jun;32(5):588-91. doi: 10.1016/j.ejso.2006.02.013. Epub 2006 Mar 29. Eur J Surg Oncol. 2006. PMID: 16569491

7

The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma.

Rosa DD, Ton NC, Clamp A, Mullamitha S, Lau S, Clayton R, Kitchener HC, Shanks JH, McVey R, Jayson GC. Rosa DD, et al. Clin Oncol (R Coll Radiol). 2007 Mar;19(2):125-8. doi: 10.1016/j.clon.2006.11.015. Clin Oncol (R Coll Radiol). 2007. PMID: 17355108

8

Weekly paclitaxel in the treatment of recurrent ovarian carcinoma.

Byrd L, Thistlethwaite FC, Clamp A, Ton C, Hasan J, Jayson GC. Byrd L, et al. Eur J Gynaecol Oncol. 2007;28(3):174-8. Eur J Gynaecol Oncol. 2007. PMID: 17624081

9

Antiangiogenic therapy for ovarian cancer.

Rosa DD, Clamp AR, Collinson F, Jayson GC. Rosa DD, et al. Among authors: clamp ar. Curr Opin Oncol. 2007 Sep;19(5):497-505. doi: 10.1097/CCO.0b013e32827035f0. Curr Opin Oncol. 2007. PMID: 17762578 Review.

10

Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma.

Clamp AR, Ryder WD, Bhattacharya S, Pettengell R, Radford JA. Clamp AR, et al. Br J Cancer. 2008 Jul 22;99(2):253-8. doi: 10.1038/sj.bjc.6604468. Epub 2008 Jul 1. Br J Cancer. 2008. PMID: 18594529 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters